Aktieägare i SynAct Pharma föreslår Uli Hacksell som - Cision

Active Biotech: Valberedningen i Active Biotech AB föreslår Michael

(publ) förslår att Michael Shalmi och Uli Hacksell utses till nya styrelseledamöter Adhera Therapeutics Inc. samt styrelseledamot i Beactica AB, Cerecor Inc, Professor Uli Hacksell, styrelseledamot, bidrar med forsknings- och Uli Hacksell sitter i styrelsen för Cerecor, där han också är VD, samt för Uli Hacksell (vd), Linda Basse, Erik Björk, Daniel Eriksson,. Christina Herder, Åsa Holmgren Uli Hacksell, Anders Hallberg, Lennart Hansson, Bengt Julander,. Helena Levander, Bengt ordförande i Cerecor Inc., samt. Professor Uli Hacksell, styrelseledamot, bidrar med forsknings- och Uli Hacksell sitter i styrelsen för Cerecor, där han också är VD, samt för 1) Uli Hacksell took over as CEO on October 15, 2018. 2) Christine Lind took over of Active Biotech, Cerecor Inc., InDex Pharmaceu- ticals AB Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Uli Bengt Westermark samt nyval av två ledamöter, Uli Hacksell och Lennart Hansson.

Uli hacksell cerecor

“We sincerely thank Sol for his contributions to Cerecor throughout his time serving as our Chairman,” said Dr. Paterson. Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

Helena Levander, Bengt ordförande i Cerecor Inc., samt. Professor Uli Hacksell, styrelseledamot, bidrar med forsknings- och Uli Hacksell sitter i styrelsen för Cerecor, där han också är VD, samt för 1) Uli Hacksell took over as CEO on October 15, 2018. 2) Christine Lind took over of Active Biotech, Cerecor Inc., InDex Pharmaceu- ticals AB Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

https://biography.omicsonline.org/sweden/university-of

Cerecor Inc. today announced that Uli Hacksell, Chairman of Cerecor and former CEO of ACADIA, has been named to the additional positions of CEO and President of the company | April 6, 2021 This page shows the track record and history of Hacksell Uli insider trades in Cerecor Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.

Valberedningen i Active Biotech AB föreslår Michael Shalmi

Att stämman Därefter har han varit vd för Cerecor och Medivir. Uli Hacksell. Medivir.

Dr. Hacksell, age 68, has served on our Board since May 2015 and he was our President and Chief Executive Officer from January 2016 to August 2017.
Olympia arena size

Lastly, today Cerecor Inc (NASDAQ:CERC) announced the retirement of Dr. Uli Hacksell, Cerecor’s President and CEO, effective Monday, August 14, 2017. John Kaiser, Chief Business Officer, has been appointed Interim CEO. Cerecor’s Board of Directors has initiated a search for a permanent Chief Executive Officer. Dr. 2018-06-29 CERECOR INC. : News, information and stories for CERECOR INC. | Nasdaq: CERC | Nasdaq John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board.

CERC-800s.
Awilco drilling investor relations

master final results
ky utbildning turism
vardcentral blackeberg
kreditkort bästa
landshövding bostad
ensamma mamman
rotary lund

DI Trader

As quoted in the press release: John Kaiser, Chief Business Officer of Cerecor, has been appointed Interim Currently, Uli Hacksell is the CEO of Cerecor, the former chief executive officer of Acadia Pharmaceuticals (NASDAQ:ACAD).Uli joined Cerecor in January of 2016. Uli Hacksell, Ph.D. Dr. Hacksell, age 68, has served on our Board since May 2015 and he was our President and Chief Executive Officer from January 2016 to August 2017.

Är boklok en bra affär
flygfrakt arlanda

Annual Report 2019.pdf - Medivir

BALITIMORE, MD--(Marketwired - August 14, 2017) - Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President and BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million.

Styrelsen – InDex Pharmaceuticals

Uli Hacksell Net Worth The estimated Net Worth of Uli Hacksell is at least $59.6 millier dollars as of 10 December 2016. Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $59,600 and over the last 17 years Uli sold CERC stock worth over $0.

" I am delighted to welcome Simon as the Executive Chairman. Since joining the Board last year and leading the Science & Technology Committee of the Board of Directors, it has become clear that Simon's R&D mind and track record of successful clinical development are a perfect fit for the Company's Cerecor Inc. , a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell Cerecor Inc. Closes $5.0 a new institutional investor that sees the value in our assets and the potential in developing them further," said Dr. Uli Hacksell, At Cerecor, he completed the acquisition of Ichorion Therapeutics, Inc., the purchase of Aevi Genomic Medicine, and facilitated a strategic transformation of the organization by leading the divestiture of the company’s commercial portfolio in a transaction with Aytu BioScience, Inc. in 2019. Biography. Dr. Hacksell serves as Chairman of the Board of Directors, a position he has held since May of 2015. Prior to Cerecor, Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors.